Atlas Trials

Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

Clinical trial NCT04631731 · UNKNOWN

Trial details

NCT number
NCT04631731
Sponsor
Western Sydney Local Health District
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Lung Cancer, Nonsmall CellRenal Cell CarcinomaMelanomaGastric CancerHepatocellular CarcinomaEndometrial CancerMesothelioma
Start date
2020-12-15
Primary completion
2024-12-10
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.